Phosphoinositide 3-kinase alpha–RAS protein–protein interaction (PI3Kα–RAS PPI)

The Phosphoinositide 3-kinase alpha–RAS protein–protein interaction (PI3Kα–RAS PPI) is a critical signaling node that facilitates the activation of the PI3K/AKT pathway by RAS GTPases. This interaction occurs when active, GTP-bound RAS (such as KRAS, HRAS, or NRAS) binds to the Ras-binding domain (RBD) located on the p110α catalytic subunit of PI3Kα (Gupta et al., 2007, Cell). This binding event is essential for the recruitment of PI3Kα to the plasma membrane, where it phosphorylates PIP2 to PIP3, initiating downstream signaling cascades that govern cell growth, survival, and metabolism (Fritsch et al., 2013, Molecular Cell). In many human malignancies, particularly those involving KRAS or PIK3CA mutations, this interaction is a key driver of oncogenesis and therapeutic resistance (Castellano & Downward, 2011, Genes & Cancer). Unlike traditional kinase inhibitors that target the ATP-binding pocket, therapeutic strategies focusing on this PPI aim to sterically hinder the RAS-PI3K interface, potentially offering a more selective way to block RAS-driven PI3K activation. Research into small molecules like Rigosertib has explored the disruption of RAS-effector interactions as a novel anti-cancer approach, though clinical development remains challenging (Athuluri-Divakar et al., 2016, Cell). The specificity of targeting this interaction could potentially reduce the systemic toxicities often associated with broad-spectrum PI3K inhibitors. Overall, the PI3Kα–RAS PPI represents a high-value target for precision medicine in oncology, especially for tumors that have become resistant to direct RAS or PI3K inhibitors.

Other names

p110α–RAS interactionPIK3CA–RAS interactionRAS–PI3Kα binding interfaceRAS–PI3K interaction

Disruption of the physical association between the RAS GTPase and the Ras-binding domain (RBD) of the p110α subunit of PI3K, preventing membrane recruitment and subsequent activation of the PI3K/AKT signaling pathway.